These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1177 related items for PubMed ID: 19723150

  • 1. Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.
    Fernandes RC, Bevilacqua JL, Soares IC, Siqueira SA, Pires L, Hegg R, Carvalho FM.
    Histopathology; 2009 Sep; 55(3):346-52. PubMed ID: 19723150
    [Abstract] [Full Text] [Related]

  • 2. Ductal invasive mammary carcinoma--clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2/neu oncoprotein.
    Recăreanu F, Simionescu C, Georgescu CV, Pirici E.
    Rom J Morphol Embryol; 2011 Sep; 52(3 Suppl):1059-64. PubMed ID: 22119825
    [Abstract] [Full Text] [Related]

  • 3. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
    Kolacinska A, Chalubinska J, Zawlik I, Szymanska B, Borowska-Garganisz E, Nowik M, Fendler W, Kubiak R, Pawlowska Z, Morawiec Z, Szemraj J.
    Neoplasma; 2012 Sep; 59(4):424-32. PubMed ID: 22489698
    [Abstract] [Full Text] [Related]

  • 4. Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.
    Kuzhan A, Adli M, Eryigit Alkis H, Caglayan D.
    J BUON; 2013 Sep; 18(3):619-22. PubMed ID: 24065473
    [Abstract] [Full Text] [Related]

  • 5. Clinicopathologic and prognostic evaluation of invasive breast carcinoma molecular subtypes and GATA3 expression.
    Demir H, Turna H, Can G, Ilvan S.
    J BUON; 2010 Sep; 15(4):774-82. PubMed ID: 21229645
    [Abstract] [Full Text] [Related]

  • 6. Male breast cancer: immunohistochemical subtypes and clinical outcome characterization.
    Sánchez-Muñoz A, Román-Jobacho A, Pérez-Villa L, Sánchez-Rovira P, Miramón J, Pérez D, Sáez MI, de Luque V, Medina L, Ramírez-Tortosa CL, Vicioso L, Medina JA, Ribelles N, Alba E.
    Oncology; 2012 Sep; 83(4):228-33. PubMed ID: 22907070
    [Abstract] [Full Text] [Related]

  • 7. Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.
    Sayed S, Moloo Z, Wasike R, Bird P, Oigara R, Govender D, Kibera J, Carrara H, Saleh M.
    Breast; 2014 Oct; 23(5):591-6. PubMed ID: 25012047
    [Abstract] [Full Text] [Related]

  • 8. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, Schnall M, Alavi A.
    Cancer; 2008 Mar 01; 112(5):995-1000. PubMed ID: 18098228
    [Abstract] [Full Text] [Related]

  • 9. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
    Arapantoni-Dadioti P, Valavanis C, Gavressea T, Tzaida O, Trihia H, Lekka I.
    J BUON; 2012 Mar 01; 17(2):277-83. PubMed ID: 22740206
    [Abstract] [Full Text] [Related]

  • 10. Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society.
    Iwase H, Kurebayashi J, Tsuda H, Ohta T, Kurosumi M, Miyamoto K, Yamamoto Y, Iwase T.
    Breast Cancer; 2010 Apr 01; 17(2):118-24. PubMed ID: 19466512
    [Abstract] [Full Text] [Related]

  • 11. High incidence and frequency of LOH are associated with aggressive features of high-grade HER2 and triple-negative breast cancers.
    Tokunaga E, Okada S, Yamashita N, Akiyoshi S, Kitao H, Morita M, Kakeji Y, Maehara Y.
    Breast Cancer; 2012 Apr 01; 19(2):161-9. PubMed ID: 21063923
    [Abstract] [Full Text] [Related]

  • 12. Hormone receptors and HER2 expression in primary breast carcinoma and corresponding lymph node metastasis: do we need both?
    Raica M, Cîmpean AM, Ceausu RA, Fulga V, Nica C, Rudico L, Saptefrati L.
    Anticancer Res; 2014 Mar 01; 34(3):1435-40. PubMed ID: 24596391
    [Abstract] [Full Text] [Related]

  • 13. Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity.
    Lin Fde M, Pincerato KM, Bacchi CE, Baracat EC, Carvalho FM.
    J Clin Pathol; 2012 Jan 01; 65(1):64-8. PubMed ID: 22039288
    [Abstract] [Full Text] [Related]

  • 14. Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. a single institution survey spanning 1998 to 2010.
    García Fernández A, Giménez N, Fraile M, González S, Chabrera C, Torras M, González C, Salas A, Barco I, Cirera L, Cambra MJ, Veloso E, Pessarrodona A.
    Breast; 2012 Jun 01; 21(3):366-73. PubMed ID: 22487206
    [Abstract] [Full Text] [Related]

  • 15. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
    Munzone E, Botteri E, Sandri MT, Esposito A, Adamoli L, Zorzino L, Sciandivasci A, Cassatella MC, Rotmensz N, Aurilio G, Curigliano G, Goldhirsch A, Nolè F.
    Clin Breast Cancer; 2012 Oct 01; 12(5):340-6. PubMed ID: 23040002
    [Abstract] [Full Text] [Related]

  • 16. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.
    Liu H, Fan Q, Zhang Z, Li X, Yu H, Meng F.
    Hum Pathol; 2008 Feb 01; 39(2):167-74. PubMed ID: 18045647
    [Abstract] [Full Text] [Related]

  • 17. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y.
    Jpn J Clin Oncol; 2012 May 01; 42(5):375-86. PubMed ID: 22450930
    [Abstract] [Full Text] [Related]

  • 18. Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.
    Nassar A, Sussman ZM, Lawson D, Cohen C.
    Breast J; 2012 Sep 01; 18(5):399-405. PubMed ID: 22882580
    [Abstract] [Full Text] [Related]

  • 19. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [Abstract] [Full Text] [Related]

  • 20. Triple-negative breast cancers: unique clinical presentations and outcomes.
    Billar JA, Dueck AC, Stucky CC, Gray RJ, Wasif N, Northfelt DW, McCullough AE, Pockaj BA.
    Ann Surg Oncol; 2010 Oct 01; 17 Suppl 3():384-90. PubMed ID: 20853062
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 59.